Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Total Liabilities (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Total Liabilities data on record, last reported at $44.6 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 6.8% year-over-year to $44.6 million; the TTM value through Sep 2025 reached $44.6 million, up 6.8%, while the annual FY2024 figure was $47.1 million, 10.43% down from the prior year.
  • Total Liabilities reached $44.6 million in Q3 2025 per SNTI's latest filing, up from -$24.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $333.0 million in Q3 2021 and bottomed at -$24.7 million in Q2 2025.
  • Average Total Liabilities over 5 years is $51.5 million, with a median of $46.1 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: soared 3073.28% in 2022, then crashed 157.65% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $36.3 million in 2021, then skyrocketed by 47.36% to $53.5 million in 2022, then decreased by 1.79% to $52.6 million in 2023, then dropped by 10.43% to $47.1 million in 2024, then dropped by 5.36% to $44.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $44.6 million in Q3 2025, -$24.7 million in Q2 2025, and $44.9 million in Q1 2025.